Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Conmed ( (CNMD) ).
On July 7, 2025, CONMED Corporation announced that Martha Aronson will resign from its Board of Directors to become the President and CEO of Merit Medical Systems, a leader in medical device development and distribution. Her departure marks the end of a tenure that began in February 2016, during which she contributed significantly to the company’s strategic growth and governance. The leadership at CONMED expressed gratitude for her service and wished her success in her new role.
The most recent analyst rating on (CNMD) stock is a Buy with a $106.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.
Spark’s Take on CNMD Stock
According to Spark, TipRanks’ AI Analyst, CNMD is a Outperform.
Conmed’s overall stock score reflects solid financial performance and positive earnings call insights, with strong revenue growth and improved guidance being the most significant factors. Technical indicators suggest neutral momentum, and valuation appears reasonable. While supply chain and international sales challenges remain, the company’s operational improvements and strategic focus provide a positive outlook.
To see Spark’s full report on CNMD stock, click here.
More about Conmed
CONMED Corporation is a medical technology company that provides devices and equipment for surgical procedures. The company’s products are used by surgeons and healthcare professionals across various specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
Average Trading Volume: 454,228
Technical Sentiment Signal: Sell
Current Market Cap: $1.68B
For a thorough assessment of CNMD stock, go to TipRanks’ Stock Analysis page.